Emphysema is characterized by the destruction of alveolar wall and enlargement of alveolar airspaces, resulting in a reduction of the total lung gas exchange area, loss of lung elastic recoil and hyperinflation. The REPAIR study (Retinoid treatment of Emphysema in Patients on the Alpha-1 International Registry) is the first proof-of-concept study of a new potential disease-modifying drug, Palovarotene ! , an orally active, gamma selective retinoid agonist in patients with emphysema secondary to alpha-1-antitrypsin deficiency (AATD) as a model population for the general smoke-induced emphysema population. This article describes the study design as well as the effectiveness of the quality control that was implemented on the key efficacy endpoints, based on data derived from the placebo-treated subjects. In this multicentre, multinational study the implementation of standardized procedures included: careful site selection, use of trained staff, regular monitoring and machine calibration, use of biological controls and regular feedback to sites by an independent quality control centre. All of these procedures resulted in high-quality measurements of lung density, spirometry, static lung volumes and gas transfer. It was also confirmed that CT lung density was the most sensitive endpoint followed by TLco, FEV 1 and RV measured by body box.
Introduction
Emphysema results from tobacco-induced inflammation and/or chronic proteinase antiproteinase imbalance in the lung [American Thoracic Society, 1995] . The resultant loss of lung parenchyma reduces the surface area available for gas exchange, causing impaired oxygen transfer finally resulting in increased pulmonary vascular resistance and right heart dysfunction. The loss of lung matrix, including elastin fibres, reduces the lung elastic recoil pressure and results in mechanical failure of the lung. Ultimately, these changes lead to hyperinflation of the lung, airflow limitation, and ventilation/perfusion mismatch. These progressive changes have been considered irreversible and therapies have focused on smoking cessation. While currently available treatments only decrease symptoms and address complications, no therapeutic intervention has demonstrated a disease-modifying effect by restoring lung structure and function [Halpin and Tashkin, 2009 ; Global Initiative for Chronic Obstructive Lung Disease, 2001] .
All trans-retinoid acid (ATRA) and other retinoids are ligands for two classes of nuclear hormone receptors, RAR and RXR, which are further divided into subtypes, i.e. RARa, RARb, RARg and RXRa, RXRb, RXRg. These receptors, when complexed to retinoic acid or other retinoids, activate and/or repress gene expression to modulate the structure and function of tissues. Temporal and spatial regulation of RAR receptor expression is required for proper tissue development and tissue maintenance. For example, RARg is highly expressed during embryonic lung development and promotes alveolar septation. Owing to the wide distribution of the RAR and RXR receptors in the body and their expression in the lungs [Mao et al. 2002; Pan et al. 1995] , it is expected that the benefit/risk ratio of using a g-selective retinoid agonist may be improved when administered for the chronic treatment of emphysema. Palovarotene ! is a potential disease-modifying treatment in development. It is a retinoic acid agonist that binds selectively to g-receptors. In a replication of a study by Massaro and Massaro [1997] , Palovarotene ! treatment showed a 3050% decrease in alveolar area and an increase in arterial oxygen partial pressure (PaO 2 ) compared with control treatment in mature rats [Berson et al. 2005; Belloni, 2001; Belloni et al. 2000 ].
The REPAIR study (Retinoid treatment of Emphysema in Patients on the Alpha-1 International Registry) is the first proof-of-concept study of Palovarotene ! , in patients with emphysema secondary to alpha-1-antitrypsin deficiency (AATD) as a model for the general emphysema population. Patients with AATD of Pi Z or Pi Null genotype were chosen as the target population for this study mainly because subjects develop parenchymal emphysema earlier in life than the general population with smokeinduced emphysema. Therefore, lung damage in AATD subjects may possibly be more amenable to repair. In addition, the rate of decline of both forced expiratory volume in one second (FEV 1 ) and carbon monoxide diffusing capacity TLco (Kco) in subjects with AATD is two-fold faster than that in subjects with smoke-induced emphysema [Dirksen et al. 1997 ] potentially making it easier to identify any treatment effect. Owing to their relatively young age, AATD subjects also have less comorbidity than subjects with exclusively smoke-induced emphysema with the same degree of reduced lung function. They thus constitute a homogeneous group of subjects suitable for early clinical studies. Furthermore, there are data available on the progression of emphysema using lung densitometry that facilitated the power calculation to determine the sample size required in this study [Dirksen et al. 1999] with density as a primary outcome. This group therefore enables the assessment of changes in lung structure induced by the underlying disease mechanism to be assessed more readily.
The loss of lung tissue is the pathological correlate for progression of emphysema and should directly cause a reduction in lung density although additional loss of density may arise from lung hyperinflation that is secondary to increased lung compliance. The lung density changes due to both processes can be measured using computed tomography (CT).
A number of studies have shown that CT lung densitometry provides an accurate characterization and quantitative assessment of changes in lung parenchyma and now is widely accepted to be the most sensitive and specific measure of emphysema in vivo. CT scanning has been validated as a measure of emphysema in studies that have shown good correlation with pathology, exercise capacity, health status and lung function [Parr et al. 2006 [Parr et al. , 2004 Newell et al. 2004; Dowson et al. 2001; Genevois et al. 1996 ; Spouge et al. 1993 ].
Furthermore, while CT densitometry is the most sensitive measure of emphysema progression, it is also a better predictor of mortality than lung function [Dirksen et al. 2009; Dawkins et al. 2003; Knudson et al. 1991] . Although these studies have led to the acceptance of this relatively novel technique, subsequent technological advances and the need for a standardization of methodology make further exploratory studies necessary.
A longitudinal study of emphysema in AATD subjects confirmed that CT densitometry of the lung was 2.5-fold more sensitive in monitoring the progression of emphysema when compared with standard lung function tests. One method of analysis of lung density uses the density value in Hounsfield units (HU) below which 15% of the lung voxels occur (15th percentile method). Using this methodology, it has been demonstrated that the annual decline of lung density of subjects with AATD-associated emphysema is 2.5±0.4 HU per year measured on a spiral CT scanner. Based on the encouraging results from this longitudinal study, the HU value of the 15th percentile has been chosen as the effect variable for the whole lung [Dirksen et al. 1999] .
In addition to the assessment of lung density using CT imaging, the present study includes a number of other efficacy endpoints that measure functional as well as symptomatic changes, including spirometry, static lung volume, gas transfer, dyspnoea index and quality of life assessments.
In view of the multiplicity of assessments included in multicentre and multinational clinical studies in general, a standardization of the procedures has become essential to minimize variation across investigational sites and to enhance the data quality.
This article describes the design of the REPAIR study as well as the quality control assessments that have been implemented on key efficacy endpoints and their efficacy and sensitivity based on data derived from the placebo subjects. All of these important aspects ultimately resulted in the generation of high-quality results and comparisons between centres.
Materials and methods

Study design
This was a randomized, multicentre, doubleblind, placebo-controlled, parallel-group study conducted at 16 sites from 10 AAT registries in The Netherlands, UK, Sweden, Canada, Australia, New Zealand, Switzerland, Spain, Belgium and Germany. Subjects were randomized using a 1 : 1 ratio to receive either 5 mg of Palovarotene or matching placebo once daily for 1 year (52 weeks).
After randomization, subjects were seen every 4 weeks at the clinics to receive study medication, check for compliance, record the occurrence of any adverse events (AEs), new concomitant treatments if applicable, measure vital signs and perform blood tests. The same assessments were also done at a 4-week follow up after the end of treatment. After randomization all efficacy assessments were made every 3 months except for lung density and exercise tests that were performed after 6 and 12 months, see Figure 1 .
Study population
Two hundred and sixty two subjects (27% females; 133 in the placebo and 129 in the active treatment group) with symptomatic emphysema (confirmed by CT), secondary to AATD, were enrolled. The patients had to have a postbronchodilator baseline FEV 1 80% and TLco (K CO ) <70% of the predicted normal value and be able to perform the incremental shuttle walk test (ISWT), without supplemental oxygen.
Current smokers as well as women of childbearing potential were excluded from the study. Patients were also excluded due to concomitant disease/condition or laboratory findings that would place the subject at undue risk or compromise the conduct or result of the study. There was no restriction regarding the use of respiratory medication prior to enrolment, except for oral steroids that should not have been used during the 28 days prior to enrolment.
The data presented in this paper is derived from the placebo-treated group; Table 1 presents the baseline demographic characteristics in this group alone. At baseline, mean postbronchodilator FEV 1 was 47% of the predicted value, mean postbronchodilator FEV 1 /forced vital capacity (FVC) ratio was 0.38, and mean TLco was 48% of the predicted value. Subjects were allowed to continue their regular respiratory medication throughout the study including: inhaled corticosteroids (ICS), long-acting beta agonists (LABA), tiotropium bromide as well as a combination of all three (Table 2 ). In addition, short-acting beta agonists were taken as needed.
Study endpoints
Lung density. The primary efficacy analysis in the present study was the comparison of volume-adjusted 15th percentile of the lung density histogram at 12 months adjusted for the baseline between the Palovarotene and placebo groups. The 15th percentile of the density histogram was the variable of choice in this trial according to the recommendation of an international workshop which concluded that a significant shift in the 15th percentile point of lung density histogram is preferable as the primary endpoint in longitudinal CT studies for assessment of emphysema progression [Newell et al. 2004 ].
Lung volume is an important confounder of CT densitometry and can cause overestimation or underestimation of progression of emphysema as well as increasing variability. Therefore, lung density was adjusted for volume to determine lung density progression independently, thereby estimating any treatment effect on tissue loss alone. The theory and methodology are described in detail elsewhere [Stoel et al. 2008 ]. In brief, the algorithm for the volume adjustment assumes that, for a given individual, there is a unique linear relationship between lung density and volume at each visit. These relationships are based on both total lung capacity (TLC) and approximate functional residual capacity ($FRC) lung density measurements at each visit by using lung volume as a covariate. By substituting the subject's mean lung volume of TLC and $FRC scans at baseline into the linear models, the adjusted lung density values are derived for each subject/visit ( Figure 2) for the baseline TLC.
Lung density was assessed using multislice computed tomography (MSCT), performed at baseline, 6 and 12 months. Two MSCT scans were performed at each visit, one scan after a breathhold TLC followed immediately by a second scan at $FRC. Qualitative assessments of baseline CT scans were undertaken by the radiologist at the site to confirm the presence of emphysema, to exclude other confounding pulmonary diseases and to rule out the presence of lung nodules which may require medical assessment. The review had to be completed within a maximum of 1 week after the CT scan.
All CT images were analysed centrally (BioClinica, Leiden, the Netherlands) using a software package PulmoCMS (Medis specials, Leiden, the Netherlands).
For quality assurance, specific guidelines were issued to facilitate the standardization of the lung density, in order to increase accuracy and to minimize variation between investigational sites. Guidelines for this study were described for the image acquisition with MSCT scanners with at least four detector rows including the calibration procedure, quality control and the image acquisition.
For each subject, the same CT scanner was used throughout the study. As the expected loss of lung tissue was about 23 HU per year, calibration of the equipment was performed as described in the following to detect and correct for any scanner drift between acquisitions. The standardized procedure included water calibration every 3 months and air calibration up to 3 hours prior to scanning a study patient. To ensure the calibration of the scanner and to keep track of possible drifts in CT density measurements due to inherent scanner performance, a dedicated foam phantom was also scanned before the start of the study and following any upgrade or maintenance of the CT scanner. Furthermore, technical details were specified to select the optimal field of view (FOV) for each patient separately at the first visit and kept constant for each patient throughout the study. Finally the height of the CT table used for each patient was constant for each subsequent visit throughout the study.
Lung function assessments. Lung functions were measured at screening, baseline and every 3 months during the study. For all lung function tests the site followed a standard procedure. All lung function test visits had to be performed at the same time of day (±2 hours) for each subject to avoid any effect of diurnal variation. Subjects had to be tested on the same set of equipment at every visit and where possible the same operator performed the tests on the same subject at each visit. All lung function tests were performed with the patient in the seated position, with their legs uncrossed and their arms on the arms of the chair.
All subjects underwent plethysmography to measure lung volumes unless factors such as claustrophobia, upper-body paralysis, obtrusive casts, or other issues limited the subject's access into the chamber. In such cases the helium dilution method was used for each visit.
The gas mixture for CO diffusion was to be kept within acceptable values for each (CO: value of first cylinder±0.025% (absolute); O 2 value of first cylinder±0.5%(absolute)) although there was some baseline variation between study sites. Certificates had to be kept in the investigator file to confirm this stability.
Spirometry and ISWT were always performed first and last respectively; but gas transfer and lung volumes could be measured in different orders. However, the same order of testing had to be performed for each individual subject at all visits.
Prior to each visit the subjects were instructed as follows: no meal for at least 2 hours before the lung function tests, no strenuous exercise for 30 minutes prior to any lung function tests, normal walking was permitted and tight/restricting clothing that prevented a full inspiration from being easily achieved was not permitted [American Thoracic Society, 1995] . Subjects using supplemental O 2 had this removed for at least 30 minutes prior to lung function testing.
Spirometry. Spirometry was performed according to the European Respiratory Society (ERS) spirometry guidelines [European Respiratory Society, 1993] . A prebronchodilator and postbronchodilator test was performed at screening to establish any degree of reversibility of the airways component of the disease. Postbronchodilator spirometry alone was performed at baseline and at 3, 6, 9 and 12 months.
All other lung function assessments, even at screening, were performed postbronchodilator.
Single-breath TLco and Kco. Single-breath TL CO and K CO were performed following the latest ERS guidelines, at least 30 minutes after bronchodilator administration [Hughes, 2000; Cotes et al. 1993] . Each TLco manoeuvre had to have an inspired volume >90% vital capacity (VC), a stable breath-hold time of 812 seconds, appropriate clearance of dead space and proper sampling/analysis of alveolar gas.
Static lung volumes: total lung capacity, functional residual capacity and residual volume. TLC, FRC and residual volume (RV) were measured by body plethysmography in most of the sites (about 75% of the subjects). In the remainder lung volumes were measured using the helium dilution technique. If a subject was unable to perform the required manoeuvres, or a site did not have access to a body box plethysmograph, then the helium dilution was an acceptable alternative. However, the same method had to be used with each subject throughout the study.
Quality assurance of lung function test. The quality assurance procedures were based on: process quality assurance in terms of equipment preparation, maintenance and calibration as well as staff training, performance of standardised test procedures and patient stability. Furthermore, assessments of both technical acceptability and reproducibility of measurements were performed by an independent quality control centre.
The lung function central laboratory assessor performed a prestudy visit to the investigational sites prior to subject enrolment to ensure standardization of equipment preparation, and staff training. Regular contact with investigational sites and the central Lab was established to provide recommendations on any repeat measurements needed, machine service or advice when changing equipment as well as feedback on the quarterly reviews of site subject quality control data.
The quality assurance (QA) procedures consisted of three parts. (1) Physical checks on equipment including routine calibration, equipment checks before subject testing sessions and routine quality control at regular intervals throughout the study. (2) Use of biological controls prior to, and biweekly throughout, the study.
(3) Regular check of subject data with regard to technical acceptability and reproducibility. Table 3 presents an overall summary of the procedures.
Prior to the study, all sites used stable biological controls (BioQC) to perform 10 baseline measurements obtained according to the acceptable American Thoracic Society (ATS)/ERS standard. The pooled mean difference from baseline to the end of the trial in the mean values of FEV 1 and FVC, lung volumes and gas transfer for the two BioQC was calculated for each site. During the study each BioQC performed regular biweekly lung function tests. Feedback was given to sites when individual drift was >2 standard deviations from baseline values. The central Core Lab reviewed the data from biological controls during the first 3 months of enrolment at each site and provided appropriate feedback to the sites on data quality and, if required, actions to be taken. If considered necessary an extra visit was undertaken by the central lab to reinstate the standard achieved at the prestudy visit.
Subject data quality control consisted of checks of technical acceptability. A number of subjects were randomly chosen for whom raw data were sent for central readings to ensure site compliance with the study manuals throughout the trial. The study required more strict repeatability criteria for spirometry and lung volumes (<100 ml) compared with the <150 ml recommended by ATS/ERS guidelines and a coefficient of variation (CV) of <5%. Similarly, acceptable criteria for both TLco and Kco were 0.5 SI and 0.05 SI, respectively, set at half of the ATS/ERS criterion. Alveolar volume (VA) reproducibility was set at <100 ml.
Incremental shuttle walk tests. ISWTs were performed at screening, baseline and after 28 and 52 weeks of treatment or at the time of any premature discontinuation. All exercise tests were performed after bronchodilator administration.
Subjects walked up and down a 10-m course delineated by two cones inset by half a metre at each end. The speed, at which subjects walked, increased every minute marked externally by an audible beep; each beep indicating the time at which the subject had to complete each 10meter shuttle. The same track was used for all assessments within a subject and arterial O 2 saturation and heart rate were recorded using pulse oximetry, before and after the test [Singh et al. 1992; Lang-Andersson et al. 1971 ]. The distance achieved was noted when the subject failed to complete a circuit in time.
Dyspnoea/breathlessness
index. Dyspnoea/ breathlessness index was assessed with baseline dyspnoea index (BDI) and transition dyspnoea index (TDI). BDI determines a score for functional impairment and magnitude of task and effort. At baseline, the status is rated from 0 (severe) to 4 (unimpaired) and the result for each of the three categories was added to develop a total score. TDI measures the change in the three categories and the score ranges from 3 (major deterioration) to þ3 (major improvement) and similarly the ratings of each category were added to obtain a final score [Mahler et al. 1984] .
Health status and quality of life questionnaire. Subjects completed two selfadministered questionnaires, St George's Hospital Respiratory Questionnaire (SGRQ) [Jones et al. 1992 ] and the Chronic Respiratory Questionnaire (CRQ) [Williams et al. 2001] , at baseline and after 28 weeks and 52 weeks of treatment or at the time of any premature trial.
Safety. Physical examination and ECG were assessed at baseline, 6 and 12 months. Adverse events, vital signs, clinical chemistry and haematology were monitored at baseline and then monthly.
To guarantee the safety of all study subjects throughout the study, an independent data safety Monitoring Board reviewed semiblinded safety summaries and all serious AEs every 3 months. At the end of each review, a certificate of nonobjection to continue the study was issued.
Statistical analyses. It was planned to enrol 130 subjects into each treatment group, with a total enrolment of 260 subjects in this study. This sample size was to provide 70% of the power to detect a treatment difference of 1 HU in lung density (primary efficacy variable) over the study period at an alpha level of 0.05 using the two-sided test with an assumed dropout rate of 15%. The assumed common standard deviation of 3.0 HU for the mean change of PD15 was based on the data from a previous study [Dirksen et al. 1999 ]. In the data reported here we analysed the progression of all effect parameters for the placebo-treated patients alone.
Sensitivity to measuring progression in placebotreated patients was defined as the mean the of change of effect parameter divided by its SD using analysis of covariance (ANCOVA). The methodology was implemented using PROC MIXED in SAS (SAS/Stat User's Guide, Version 8, 1999, SAS Institute Inc, Cary, NC) . Finally, the Spearman correlation between baseline values and progression values was calculated.
The study was performed in accordance with principles outlined in the 'Guidelines for Good Clinical Practice' [ICH Guidelines, 1997] which has its basis in the principles of the Declaration of Helsinki (updated with a note of clarification on paragraph 29 added by the WMA general Assembly, Washington, DC, 2002) as well as regulations of the country where the study was conducted.
Results
Quality control of study endpoints CT lung densitometry. Analysis of the longitudinal data of the images acquired from all scanners at different centres at different time points throughout the study showed that the majority of CT scanners were stable over a period of more than 2 years. There were some scanners showing a gradual drift but these changes were well within the predefined acceptable range of ±10 HU, for which the software was able to compensate effectively, when applied to the patient CT data (see Figure 3 ). The SD of the differences of the CT scanners at the different hospitals ranged between 0.27 and 1.34 HU (or grams per litre) based on phantom analysis.
Lung function assessments. The spirometry CV at baseline and at the end of the trial phase of the study were <5%, except for one site where it was 5.8%. The average combined BioQC data from all sites showed a difference of <100 ml for FEV 1 and FVC. Nine of 32 BioQC differed from baseline by >100 ml in FEV 1 but only 3/32 were >150 ml. Pooled mean difference±SD for two BioQC from baseline for FEV 1 and FVC were 90±80 ml and 80±60 ml, respectively. The overall FEV 1 and FVC CV at baseline and at the end of the study was <5% in all BioQC and for FEV 1 was <3% in all BioQC, and <3% for FVC in 11 of the 16 sites.
All but three sites were within ATS/ERS repeatability criteria for lung volumes with 88% and 44% sites achieving the <5% target for TLC and FRC, respectively. The CV between sites was <10% for TLC and FRC. Twelve of 16 sites achieved a within-site CV of <10% for RV and between 12% and 16% for TLC and FRC. Overall when BioQC values were averaged, the combined sites mean±SD volume difference across the trial from the baseline data was 110±9 ml, 130±9 ml and 110±10 ml for TLC, FRC and RV, respectively.
All sites were within the 10% intersession specificity recommended by the ATS/ERS guidelines. For TL CO , only two sites failed to achieve the trial standard and all but one were within the ATS/ERS repeatability criteria. All sites achieved the required guideline standard and repeatability for K CO .
All sites achieved a CV of <7% for TL CO and 11/ 16 achieved <5% and 14/16 achieved a CV of <7% and 12/16 centres achieved <5% for K CO .
For VA, 10/16 sites achieved the target of <100 ml and 13/16 were within the ATS/ERS standard of <150 ml for the mean BioQC values during the trial. These data demonstrate that robust quality control in multisite trials can be achieved for gas transfer measurement within the ATS/ERS standards.
Reproducibility
of lung function assessments. Overall, subject data collection and reporting were completed with satisfactory site compliance with the procedures. There were some differences between sites, but good consistency within each site. Figure 4 shows the reproducibility of different lung function tests presented as the proportion of test values that were outside the study-specific criteria. This was low for K CO (1.3%), TL CO (2.7%) and FEV 1 (6.7%). However, more individual values were outside the study reproducibility criteria for FVC (11.6%), VC (18.5%), total gas volume (26.6%), TLC (28.6%), RV (53.7%) and inspiratory capacity (IC) (55.5%).
Progression of emphysema. In this study, placebo-treated patients showed an average decline in postbronchodilator FEV 1 of 50 (SD±139) ml/ year, a decline of TL CO of 0.25±0.496 mmol/ min/kPa and a decline of lung density of 1.81±3.651 HU over 1 year.
Endpoint sensitivity. Figure 5 shows the sensitivity of lung function tests to detect change in the placebo group calculated as mean changes from baseline divided by SD. The sensitivity varied between 4.9 and 0.1, the highest value of 4.9 was for 15th percentile lung density followed by 4.6 for TL CO , 3.5 for FEV 1 and 3.2 for RV by body box. The lowest sensitivity of 0.5 was for FRC by body box.
The sensitivity of dyspnoea index and quality of life assessments is shown in Figure 6 . The highest sensitivity of 1.7 was for CRQ emotional function score and lowest of 0.1 was for total scores of the SGRQ. Feb-06
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Acquisition date Difference from baseline (HU) Figure 3 . Stability of CT measured as changes in the density measured in the foam phantom during the study period. Each curve represents one of the CT scanners used in the trial. Table 4 shows the Spearman correlation coefficients and p-values at baseline between lung density 15th percentile (HU) and lung functions.
Correlation between baseline structural and functional endpoints
Discussion
The assessment of the progression of emphysema is critical and requires multicentre studies of disease-modifying drugs in conditions such as AATD. However, this creates practical problems in establishing and monitoring the highquality measurements necessary to deliver meaningful results.
REPAIR was a proof-of-concept study with a potential disease-modifying drug in the development for the chronic treatment of emphysema and was designed in the absence of benchmark studies for the assessment of efficacy of such Figure 5 . The sensitivity of lung function assessments calculated as the mean change from baseline/SD for the patient group on placebo is shown in descending order: 15 th percentile of lung density histogram; transfer factor of the lung for carbon monoxide (TLco); forced expiratory volume in one second (FEV 1 ); residual volume (RV); vital capacity (VC), carbon monoxide uptake from the lung (Kco), total lung capacity (TLC); incremental shuttle walk test (ISWT); inspiratory capacity (IC). a class of drugs. The choice of the primary endpoint was based on the available literature showing that CT-based densitometry accurately characterizes structural changes reflecting disease progression and can also measure the potential effects of pharmacological intervention [Dirksen et al. 1999 [Dirksen et al. , 1997 . However, at present an increase in lung density has to be associated with beneficial clinical or accepted lung functional changes, and not reflect adverse pathological changes such as fibrosis. Therefore, a number of functional endpoints including spirometry, static lung volumes and gas transfer as well as symptomatic assessments of dyspnea, quality of life and exercise capacity, were included in the current study to monitor any potential drug effects of Palovarotene in subjects with emphysema.
In the absence of established international guidelines to guarantee the reliability of CT densitometry data in this study, a quality assurance procedure based on the current experience within this field was implemented [Stoel et al. 2008] . The results showed that CT is a reliable endpoint for disease progression with higher sensitivity than conventional or other functional and symptomatic measures [Bakker et al. 2005] .
At baseline, we showed highly statistically significant correlations between 15th percentile and DL CO , K CO , TLC and RV, although the Spearman correlations were not as strong as previously reported [Gevenois et al. 1996 ]. This may reflect the multicentre nature of the data or the broader range of previous cross-sectional studies. For instance, the mean K CO of 41.7% predicted measured in the current study is significantly lower than reported previously (60.9% predicted) in a similar study on progression of emphysema in AATD [Stolk et al. 2007 ]. As shown in Table 4 , the correlation between lung density and Kco was around 0.30, considerably lower than that reported in the literature [Stolk et al. 2007; Gevenois et al. 1996] . A subanalysis of data from individual sites which each contributed more than 20 patients to the study (66% of the study population) gave correlation coefficients between 0.140 and 0.617 for densitometry versus K CO . Furthermore, the analysis showed that only one site appeared to be an outlier, however excluding this site from the calculation only increased the correlation from 0.30 to 0.384. This site with the lowest correlation (0.14) was amongst those with the best reproducibility of lung density as well as gas transfer measures assessed by the CT phantom and the biological controls, respectively. Owing to our stringent quality control strategy, we suggest that the poor correlation between lung density and gas transfer at this site (n ¼ 22) that may represent a different phenotypic subset and further studies are underway to explore this possibility.
In this study we found that CT lung density and TL CO were almost equally sensitive at detecting changes in our study population although the decline of these two parameters did not correlate. This may reflect the short time frame over which change has been assessed or that gas transfer and emphysema progression occur differentially due to the signal being generated by different regions of the lung [Parr et al. 2006 ]. Although the CT densitometry showed the highest sensitivity over a 1-year period, the data may reflect some degree of heterogeneity that require further exploration of disease biology including obtaining a better understanding of the pathophysiology of emphysema even in this relatively homogeneous population.
The REPAIR study did characterize AATD patients into four different domains (structural, functional, symptomatic and exercise) that confirm that the noise-to-signal ratio of the CT scan exceeds that of all other measures. The cross-sectional correlation of densitometry with other measures supports its use as a surrogate of efficacy. An analogy can be made with osteoporosis where bone mineral density (BMD) assessments were proposed to be a surrogate marker of efficacy for fractures that take a long time to develop.
BMD substantially helped the characterization of patients at risk of developing fractures as well as the development of new drugs [Melton et al. 2003; Sarkar et al. 2002] . Future studies will confirm whether lung densitometry plays the same role.
In line with international guidelines such as ATS/ ERS recommendations, the current study has implemented a comprehensive standardized quality assurance process to increase the accuracy and minimize the variation between sites in lung function assessments. The study results demonstrated that standardization and centralized control are able to achieve high-quality data that is independent of countries, using lung function training programmes by professional bodies. The careful selection of sites, use of trained staff, regular feedback and monitoring of equipment and using BioQC can achieve high-quality pulmonary function tests with regards to a reduction of variability over time. None of the centres was poorly repeatable in any lung volume measurements. However, sites that showed higher variability were usually related to only one of the BioQC being poorly repeatable or equipment/software being changed during the trial. A reduction in the overall variability in the change from baseline in different efficacy endpoints helps to decrease the number of subjects needed to demonstrate treatment effects and the data presented here can be used for power calculations in future studies.
One shortcoming in our study was the lower reproducibility rates for lung volume assessments as compared with other lung function assessments. It is generally acknowledged that lung volume assessments have less reproducibility than spirometry and within-subject variability may not be the same for all subjects, particularly for those with airway obstruction where FRC and RV are increased [Hankinson et al. 1998 ].
Despite the poor reproducibility of RV, its mean change in our subjects assessed over 12 months measured at quarterly intervals appeared rather sensitive when expressed as CV. This is an unexpected finding but is in line with our observation that baseline RV correlates best with baseline lung density (Table 3 ).
In conclusion, in this multicentre, multinational study the implementation of standardized procedures including careful site selection, use of trained staff, regular monitoring and machine calibration, use of biological control and regular feedback, has resulted in high-quality measurements of lung density, spirometry, static lung volumes and gas transfer.
It was confirmed that CT lung density is the most sensitive endpoint followed by TL CO , FEV 1 and RV measured by body box. Full characterization of emphysema in AATD patients as in REPAIR may help to us to better understand how structural changes in lung density predict and precede functional/symptomatic changes. This will consolidate it as a validated surrogate marker of efficacy for individual patients or in the setting of clinical studies evaluating a drug effect. The study highlights the need for quality control in limited but well-established centres for such complex studies.
